Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
Top Cited Papers
- 3 August 2017
- journal article
- clinical trial
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 377 (5), 431-441
- https://doi.org/10.1056/nejmoa1707278
Abstract
Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran. We performed a multicenter, prospective, open-label study to determine whether 5 g of intravenous idarucizumab would be able to reverse the anticoagulant effect of dabigatran in patients who had uncontrolled bleeding (group A) or were about to undergo an urgent procedure (group B). The primary end point was the maximum percentage reversal of the anticoagulant effect of dabigatran within 4 hours after the administration of idarucizumab, on the basis of the diluted thrombin time or ecarin clotting time. Secondary end points included the restoration of hemostasis and safety measures. A total of 503 patients were enrolled: 301 in group A, and 202 in group B. The median maximum percentage reversal of dabigatran was 100% (95% confidence interval, 100 to 100), on the basis of either the diluted thrombin time or the ecarin clotting time. In group A, 137 patients (45.5%) presented with gastrointestinal bleeding and 98 (32.6%) presented with intracranial hemorrhage; among the patients who could be assessed, the median time to the cessation of bleeding was 2.5 hours. In group B, the median time to the initiation of the intended procedure was 1.6 hours; periprocedural hemostasis was assessed as normal in 93.4% of the patients, mildly abnormal in 5.1%, and moderately abnormal in 1.5%. At 90 days, thrombotic events had occurred in 6.3% of the patients in group A and in 7.4% in group B, and the mortality rate was 18.8% and 18.9%, respectively. There were no serious adverse safety signals. In emergency situations, idarucizumab rapidly, durably, and safely reversed the anticoagulant effect of dabigatran. (Funded by Boehringer Ingelheim; RE-VERSE AD ClinicalTrials.gov number, NCT02104947.)Keywords
This publication has 18 references indexed in Scilit:
- A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatranThrombosis and Haemostasis, 2015
- Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trialThe Lancet, 2015
- Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatranThrombosis and Haemostasis, 2015
- The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation PatientsJournal of the American College of Cardiology, 2014
- Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major BleedingCirculation, 2013
- A specific antidote for dabigatran: functional and structural characterizationBlood, 2013
- Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatranBlood Coagulation & Fibrinolysis, 2012
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patientsJournal of Thrombosis and Haemostasis, 2009
- Dabigatran versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2009
- Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran EtexilateClinical Pharmacokinetics, 2008